Female gender has been associated with better outcomes in schizophrenia spectrum disorders (SSDs). This study investigated gender differences in recovery-related outcomes and psychiatric rehabilitation needs in a multicenter sample of patients with SSD.
Although psychotherapy is available via the Veterans Health Administration, most veterans diagnosed with posttraumatic stress disorder (PTSD) receive pharmacotherapy. This study evaluated longitudinal prescription practice trends for veterans with PTSD.
The COVID-19 pandemic has affected the daily life of millions worldwide, with still unclear effects on mental health. This study examined patterns in pediatric psychiatric visits to hospital emergency departments in Italy during the pandemic lockdown.
Here, the authors provide primary care providers a foundation for understanding pediatric hyperkinetic movement disorders, including tips on creation of a differential diagnosis, assessment of risk factors, and guidance on management strategies.
In this letter, Dr Hernandez and colleagues reply to a letter from Brigido et al that comments on their recent article on the impact of comorbid posttraumatic stress disorder on outcomes of treatment with repetitive transcranial magnetic stimulation in depressed veterans.
This letter to the editor builds on the findings of a recent article by Hernandez and colleagues on the impact of comorbid posttraumatic stress disorder on outcomes of treatment with repetitive transcranial magnetic stimulation in depressed veterans.
Psychiatric symptoms in empty sella are uncommon, but empty sella syndrome has been reported to be present along with psychosis. This report presents a case of Wilson’s disease with psychotic presentation and empty sella syndrome in an adolescent.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”